Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroectodermal Tumors, Primitive 2Uterine Neoplasms 1Tuberous Sclerosis 1Perivascular Epithelioid Cell Neoplasms 1Neuroendocrine Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Angiomyolipoma 1

Interventions

Sirolimus 7Everolimus 5ganaxolone 1dactolisib 1Vigabatrin 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Propranolol 1Aspirin 1Anticonvulsants 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Tuberous Sclerosis × dactolisib × Clear all
NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Novartis

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡